InsiderSource

Novo Holdings A/S

10% Owner · SEC CIK 1388325
Insider at COAG Hemab Therapeutics Holdings, Inc. AVLN Avalyn Pharma Inc. MPLT MapLight Therapeutics, Inc. IOBT IO Biotech, Inc. SPRB SPRUCE BIOSCIENCES, INC. MGX Metagenomi, Inc. CYT Cyteir Therapeutics, Inc. IRON Disc Medicine, Inc. RPHM Reneo Pharmaceuticals, Inc. EWTX Edgewise Therapeutics, Inc. BOLT Bolt Biotherapeutics, Inc. CMPI Checkmate Pharmaceuticals, Inc. ACLX Arcellx, Inc. UTRS MINERVA SURGICAL INC VERV Verve Therapeutics, Inc. INGN Inogen Inc GRTX Galera Therapeutics, Inc. INZY Inozyme Pharma, Inc. GLTO Galecto, Inc. EAR Eargo, Inc. ALGS Aligos Therapeutics, Inc.
Advertisement

Buy track record

How this insider's open-market purchases have performed
50%
of buys now in profit
5 up · 5 down
Avg return since buy+38.2%
Median return−43.8%
Best trade+547.2%
Worst trade−100.0%
Buys scored10 (+7 n/a)
Average return by holding period — separates good entry timing from riding one long winner
After 1 month −1.9% 20% won · 10 trades
After 3 months −7.5% 22% won · 9 trades
After 6 months −14.2% 33% won · 9 trades
After 12 months −20.6% 38% won · 8 trades
DateCompany90d trendBuy priceValueΔOwn1M3M6M12MTo date
May 1, 2026 AVLN $18 $10M +17% −10.7% — — — +0.8%
Oct 28, 2025 MPLT $17 $16.2M +35% −18.6% +12.6% +81.0% — +65.7%
Feb 13, 2024 MGX $15 $12M +85% −5.2% −44.0% −72.2% −79.0% −89.7%
Feb 9, 2024 MGX $10 $1.03M NEW +16.4% −33.2% −72.1% −76.4% −88.4%
Feb 16, 2023 SPRB $3 $7M +49% −8.8% −12.4% −11.6% +100.0% −99.6%
Sep 14, 2022 EWTX $10 $5M +8.7% −0.5% −22.7% −26.4% −35.7% +232.7%
Feb 8, 2022 ACLX $15 $12.5M +26% −3.6% −52.0% +9.9% +75.2% +547.2%
Oct 26, 2021 UTRS $12 $6.96M +39% −27.7% −49.0% −65.5% −95.7% −100.0%
Mar 30, 2021 EWTX $16 $10M +13% −8.3% −31.7% −46.8% −70.3% +11.6%
Oct 20, 2020 ALGS $15 $3M +8.3% +47.5% +164.7% +76.0% +17.7% −98.4%
How this is calculated. We score only open-market purchases (SEC code P) — the buys that carry real signal. Each trade's return is measured from the adjusted closing price on the purchase date to the latest close, accounting for stock splits and dividends. The 1M/3M/6M/12M columns show the same trade's return after each fixed holding period; a dash means that horizon hasn't elapsed yet or isn't priceable. Sales are excluded because insiders sell for many routine reasons. With only 10 scored trades, treat this as a small sample, not a verdict.
Advertisement
Open-market buys
$122.58M
17 trades
Open-market sells
$166.47M
38 trades
Net flow
−$43.89M
Net selling
Total filings
69
transactions shown

Full transaction history

All Form 4 activity across every company, newest first
View on SEC EDGAR ↗
AVLN
Avalyn Pharma Inc.
Buy Novo Holdings A/S · 10% Owner · Open-market purchase · filed May 5, 2026 ΔOwn +17%

Novo Holdings A/s, AVLN's 10% owner, spent $10M of their own money on 555,555 shares at $18, growing their stake 17%.

+$10M
555,555 sh @ $18
MPLT
MapLight Therapeutics, Inc.
Buy Novo Holdings A/S · 10% Owner · Open-market purchase · filed Oct 30, 2025 ΔOwn +35%

Novo Holdings A/s, MPLT's 10% owner, spent $16.2M of their own money on 952,941 shares at $17, growing their stake 35%.

+$16.2M
952,941 sh @ $17
Advertisement
IOBT
IO Biotech, Inc.
Sell Novo Holdings A/S · 10% Owner · Open-market sale · filed Jul 26, 2024 ΔOwn −0.5%

Novo Holdings A/s sold $30.8K of IOBT, trimming their stake 1%.

−$30.8K
23,478 sh @ $1
IOBT
IO Biotech, Inc.
Sell Novo Holdings A/S · 10% Owner · Open-market sale · filed Jul 26, 2024 ΔOwn −1.2%

Novo Holdings A/s sold $68.3K of IOBT, trimming their stake 1%.

−$68.3K
51,522 sh @ $1
IOBT
IO Biotech, Inc.
Sell Novo Holdings A/S · 10% Owner · Open-market sale · filed May 14, 2024 ΔOwn −13%

Novo Holdings A/s sold $802.5K of IOBT, trimming their stake 13%.

−$802.5K
658,809 sh @ $1
SPRB
SPRUCE BIOSCIENCES, INC.
Sell Novo Holdings A/S · 10% Owner · Open-market sale · filed Mar 25, 2024 ΔOwn −15%

Novo Holdings A/s sold $351K of SPRB, trimming their stake 15%.

−$351K
465,021 sh @ $1
SPRB
SPRUCE BIOSCIENCES, INC.
Sell Novo Holdings A/S · 10% Owner · Open-market sale · filed Mar 20, 2024 ΔOwn −11%

Novo Holdings A/s sold $264.1K of SPRB, trimming their stake 11%.

−$264.1K
359,979 sh @ $1
SPRB
SPRUCE BIOSCIENCES, INC.
Sell Novo Holdings A/S · 10% Owner · Open-market sale · filed Mar 20, 2024 ΔOwn −15%

Novo Holdings A/s sold $447.7K of SPRB, trimming their stake 15%.

−$447.7K
593,000 sh @ $1
SPRB
SPRUCE BIOSCIENCES, INC.
Sell Novo Holdings A/S · 10% Owner · Open-market sale · filed Mar 20, 2024 ΔOwn −18%

Novo Holdings A/s sold $647K of SPRB, trimming their stake 18%.

−$647K
842,020 sh @ $1
SPRB
SPRUCE BIOSCIENCES, INC.
Sell Novo Holdings A/S · 10% Owner · Open-market sale · filed Mar 18, 2024 ΔOwn −28%

Novo Holdings A/s sold $1.7M of SPRB, trimming their stake 28%.

−$1.7M
1.91M sh @ $1
MGX
Metagenomi, Inc.
Buy Novo Holdings A/S · 10% Owner · Open-market purchase · filed Feb 15, 2024 ΔOwn +85%

Novo Holdings A/s, MGX's 10% owner, spent $12M of their own money on 800,000 shares at $15, growing their stake 85%.

+$12M
800,000 sh @ $15
MGX
Metagenomi, Inc.
Buy Novo Holdings A/S · 10% Owner · Open-market purchase · filed Feb 15, 2024 ΔOwn NEW

Novo Holdings A/s, MGX's 10% owner, spent $1.03M of their own money on 100,000 shares at $10, opening a brand-new position.

+$1.03M
100,000 sh @ $10
IOBT
IO Biotech, Inc.
Sell Novo Holdings A/S · 10% Owner · Open-market sale · filed Feb 13, 2024 ΔOwn −11%

Novo Holdings A/s sold $988.4K of IOBT, trimming their stake 11%.

−$988.4K
658,809 sh @ $2
IOBT
IO Biotech, Inc.
Buy Novo Holdings A/S · 10% Owner · Open-market purchase · filed Aug 11, 2023 ΔOwn +76%

Novo Holdings A/s, IOBT's 10% owner, spent $5M of their own money on 2.47M shares at $2, growing their stake 76%.

+$5M
2.47M sh @ $2
CYT
Cyteir Therapeutics, Inc.
Sell Novo Holdings A/S · 10% Owner · Open-market sale · filed Jul 20, 2023 ΔOwn −2.8%

Novo Holdings A/s sold $275.1K of CYT, trimming their stake 3%.

−$275.1K
100,000 sh @ $3
CYT
Cyteir Therapeutics, Inc.
Sell Novo Holdings A/S · 10% Owner · Open-market sale · filed Jul 3, 2023 ΔOwn −5.2%

Novo Holdings A/s sold $529.3K of CYT, trimming their stake 5%.

−$529.3K
200,937 sh @ $3
IRON
Disc Medicine, Inc.
Sell Novo Holdings A/S · 10% Owner · Open-market sale · filed Jun 28, 2023 ΔOwn −53%

Novo Holdings A/s sold $57.63M of IRON, trimming their stake 53%.

−$57.63M
1.25M sh @ $46
CYT
Cyteir Therapeutics, Inc.
Sell Novo Holdings A/S · 10% Owner · Open-market sale · filed Jun 28, 2023 ΔOwn −0.8%

Novo Holdings A/s sold $56.7K of CYT, trimming their stake 1%.

−$56.7K
31,978 sh @ $2

Frequently asked questions

How is Novo Holdings A/S's win rate calculated?

We take every open-market purchase (SEC code P) we can match to a stock price, then compare the split- and dividend-adjusted price on the purchase date to the most recent close. The win rate is the share of those buys currently trading above the purchase price. Sales and share grants are not scored.

Why are some buys not included in the score?

A purchase is excluded if we can't price it — for example if the ticker is missing from the filing, the company has been delisted, or the security isn't a common stock we can match to market data. Excluded counts are shown next to the scored total.

What do the 1M / 3M / 6M / 12M columns mean?

They show each purchase's return after a fixed holding period — one, three, six, and twelve months from the buy date — using split- and dividend-adjusted prices. This separates good entry timing from simply holding a long-running winner. A dash means that horizon hasn't elapsed yet for that trade, or the stock couldn't be priced at that date.

Does a high win rate mean I should copy this insider?

No. Past performance does not predict future results, sample sizes are often small, and an insider's edge in their own company doesn't transfer to yours. This is context, not a recommendation. InsiderSource is not investment advice.

Where does this data come from?

Trades come from Novo Holdings A/S's SEC Form 4 filings on EDGAR. Prices come from public market data and are split/dividend-adjusted. Always verify against the original filings before acting.